In a report released on November 14, Andrew Berens from SVB Securities maintained a Buy rating on Hookipa Pharma (HOOK – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $1.17.
Berens covers the Healthcare sector, focusing on stocks such as AVEO Pharma, Seagen, and Merus. According to TipRanks, Berens has an average return of 4.4% and a 46.55% success rate on recommended stocks.
Currently, the analyst consensus on Hookipa Pharma is a Strong Buy with an average price target of $7.60, which is a 549.57% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.
Based on Hookipa Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.75 million and a GAAP net loss of $16.36 million. In comparison, last year the company earned a revenue of $5.38 million and had a GAAP net loss of $17.15 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body’s immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
Read More on HOOK: